申请人:Astellas Pharma Inc.
公开号:EP3095781A1
公开(公告)日:2016-11-23
[Problem] To provide a compound useful as a MT1 and/or MT2 receptor agonist. [Solution] The present inventors have studied on MT1 and/or MT2 receptor agonists, and have confirmed that indole compounds have the activity. As a result, the present invention is accomplished. That is, a compound represented by formula (I) or a salt thereof according to the present invention has a MT1 and/or MT2 receptor agonistic activity and has a low ability of migrating into the central nervous system. Therefore, the compound or a salt thereof can be used as a peripheral MT1 and/or MT2 receptor agonist, and therefore can be used as a therapeutic and/or prophylactic agent for urinary incontinence, particularly stress urinary incontinence and mixed urinary incontinence.
[问题]提供一种可作为 MT1 和/或 MT2 受体激动剂的化合物。[解决方案] 本发明人对 MT1 和/或 MT2 受体激动剂进行了研究,并确认吲哚化合物具有这种活性。因此,本发明得以实现。也就是说,根据本发明,由式(I)代表的化合物或其盐具有 MT1 和/或 MT2 受体激动活性,并且迁移到中枢神经系统的能力较低。因此,该化合物或其盐可用作外周 MT1 和/或 MT2 受体激动剂,从而可用作尿失禁,特别是压力性尿失禁和混合性尿失禁的治疗和/或预防剂。